Home The History of Synthetic Biology Designing Synthetic Biotics Pipeline Our People Leadership Board of Directors Founders and Advisors Investors + Media Company Overview News News Releases In the News Events & Presentations Events Presentations Publications Stock Information Stock Quote & Chart Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Board Diversity Matrix Financials Quarterly Results Investor Resources FAQs Contact IR Email Alerts RSS Feeds Synlogic Reminds Stockholders of 2023 Annual General Meeting Details Read more about Synlogic Reminds Stockholders of 2023 Annual General Meeting Details Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria Read more about Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference Read more about Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference Synlogic to Present at the Jefferies Global Healthcare Conference Read more about Synlogic to Present at the Jefferies Global Healthcare Conference Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update Read more about Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria Read more about Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates Read more about Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria Read more about Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting Read more about Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference Read more about Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to Investor Resources Contact IR Investor FAQs RSS Feeds Investor Email Alerts Email
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details Read more about Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria Read more about Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference Read more about Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
Synlogic to Present at the Jefferies Global Healthcare Conference Read more about Synlogic to Present at the Jefferies Global Healthcare Conference
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update Read more about Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria Read more about Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates Read more about Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria Read more about Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting Read more about Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference Read more about Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference